Category Press Releases

Median Technologies Releases Q3 2024 Operational and Financial Update

eyonis™ LCS Achieves Key Milestones in REALITY Study; Upcoming Webcast Scheduled Key Highlights: Operational and Financial Overview:Median Technologies (FR0011049824, ALMDT, PEA/SME eligible) announced that its Board of Directors approved the consolidated IFRS financial statements for H1 2024 on October 23,…

Read MoreMedian Technologies Releases Q3 2024 Operational and Financial Update

Groundbreaking AI-Powered Solutions for Consumer-Controlled Health Information Management

YourHealth Launches YourHealth Life: A Revolutionary Subscription-Based Health Management Tool YourHealth, a leader in consumer-controlled health applications, is thrilled to announce the launch of YourHealth Life, an innovative suite of subscription-based features designed to significantly enhance the consumer health management…

Read MoreGroundbreaking AI-Powered Solutions for Consumer-Controlled Health Information Management

Valor Compounding Pharmacy Seeks New Partnerships with Medical Practices and Hospital Systems

Valor Compounding Pharmacy Invites New Partnerships with Medical Practices and Hospital Systems Valor Compounding Pharmacy, a prominent provider of compounded medications, is excited to announce its initiative to form new partnerships with medical practices and health systems. This effort aims…

Read MoreValor Compounding Pharmacy Seeks New Partnerships with Medical Practices and Hospital Systems

MedGenome Names Felix Olale, M.D., Ph.D., as CEO and Jennifer Rose as CCO to Drive U.S. Expansion

New Leadership Team Set to Drive Growth and Innovation in Precision Medicine MedGenome, a leader in multiomics and precision medicine, has announced the appointment of Felix Olale, M.D., Ph.D., as President and Chief Executive Officer, and Jennifer Rose as Executive…

Read MoreMedGenome Names Felix Olale, M.D., Ph.D., as CEO and Jennifer Rose as CCO to Drive U.S. Expansion

NImmune Biopharma Secures Asian Rights to Develop and Commercialize Omilancor

NImmune Biopharma, a late-clinical-stage biopharmaceutical company specializing in precision inflammation and immunology (I&I) therapeutics, has announced the acquisition of development and commercialization rights to omilancor across several Asian markets, including China, Hong Kong, Taiwan, South Korea, and others. This transaction…

Read MoreNImmune Biopharma Secures Asian Rights to Develop and Commercialize Omilancor

Nucleus RadioPharma Boosts Radiopharmaceutical R&D and Production to Address U.S. Supply Chain Challenges

Nucleus RadioPharma announced the development of two new facilities, totaling over 100,000 square feet, in Mesa, Arizona, and Spring House, Pennsylvania. These state-of-the-art sites will integrate research, development, and commercial production under one roof, providing significant time and scale advantages…

Read MoreNucleus RadioPharma Boosts Radiopharmaceutical R&D and Production to Address U.S. Supply Chain Challenges

Nuclidium Announces First Patient Imaging in Phase 1 Trial of 61Cu-based Radiotracer for PSMA-positive Prostate Cancer

NUCLIDIUM today announced the successful imaging of the first patient in a Phase 1 clinical trial evaluating its radiotracer candidate as a safe and effective diagnostic and disease-staging tool in prostate cancer patients. The candidate, 61Cu-NuriPro™ (61Cu-NODAGA-PSMA I&T), is part…

Read MoreNuclidium Announces First Patient Imaging in Phase 1 Trial of 61Cu-based Radiotracer for PSMA-positive Prostate Cancer

Blue Lake Biotechnology and CyanVac Announce Presentation on Intranasal Vaccine Candidates at the International Society for Vaccines Annual Congress

Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the full breadth of the immune system to protect against serious infectious diseases, and its affiliate CyanVac LLC, today announced the presentation of…

Read MoreBlue Lake Biotechnology and CyanVac Announce Presentation on Intranasal Vaccine Candidates at the International Society for Vaccines Annual Congress

Ferring Pharmaceuticals Showcases Commitment to Fertility Care at 2024 ASRM Congress

Ferring Pharmaceuticals will present new research across four abstracts at the 2024 American Society for Reproductive Medicine (ASRM) Congress, taking place from October 19-23 in Denver, Colorado, and online. The abstracts include two oral and two poster presentations, reflecting Ferring’s…

Read MoreFerring Pharmaceuticals Showcases Commitment to Fertility Care at 2024 ASRM Congress

Vertex to Present Phase 3 Data on Suzetrigine as a Pain Signal Inhibitor at ASA Meeting

Vertex Pharmaceuticals (Nasdaq: VRTX) announced that it will present Phase 3 data on suzetrigine, an investigational oral NaV1.8 pain signal inhibitor for moderate-to-severe acute pain, at the American Society of Anesthesiologists (ASA) annual meeting from October 18-22, 2024, in Philadelphia,…

Read MoreVertex to Present Phase 3 Data on Suzetrigine as a Pain Signal Inhibitor at ASA Meeting